P&G earnings preview: analysts see sales growth despite premium valuation

Consumer products behemoth Procter & Gamble Company (PG), is scheduled to unveil its third-quarter fiscal 2026 financial results on April 24, ahead of the market opening, with analysts anticipating year-over-year growth in both sales and earnings.

For the fiscal third quarter, the Zacks Consensus Estimate forecasts Procter & Gamble will report revenues of $20.6 billion, which represents a projected 4.2% increase compared to the reported figure from the same quarter last year. 

The consensus also pegs PG's earnings at $1.57 per share, an expected 2% rise from the actual earnings of the year-ago quarter. This consensus estimate for earnings has remained consistent over the last 30 days.

PG is projected to achieve a 3.7% year-on-year revenue increase this quarter, according to market expectations. This anticipated growth marks a positive shift, contrasting with the 2.1% decline in revenue recorded during the same quarter last year.

Despite having missed Wall Street's revenue estimates multiple times in the last two years, analysts covering PG have generally reconfirmed their estimates over the past 30 days. This suggests that analysts largely anticipate the company's business performance to remain steady as it approaches the upcoming earnings release.

Peer comparisons and stock performance

Insights from PG's consumer staples peers, some of which have already released their Q1 earnings, offer clues for P&G's upcoming report. WD-40, for instance, surpassed analyst expectations by 4.7% with year-on-year revenue growth of 10.7%. 

Conversely, Cal-Maine reported a substantial 53% revenue decline but still managed to top estimates by 3.8%. Following their respective announcements, WD-40's stock dipped by 4%, and Cal-Maine's fell by 1.3%.

Investor sentiment in the consumer staples sector has been positive, with average share prices climbing 4.6% in the past month. 

In contrast, Procter & Gamble's stock price remained flat over the same period. The company is approaching its earnings release with an average analyst price target of $163.59, significantly higher than its current share price of $142.97.

Over the last six months, the PG stock has demonstrated better performance than The Clorox Company (CLX), which experienced a 14.4% decline. However, PG's stock trailed that of its rivals, as Colgate-Palmolive Company (CL) and Church & Dwight Co., Inc. (CHD) saw gains of 6.2% and 7.4%, respectively, over the same period.

Valuation and near-term risk outlook

PG's valuation, at a forward 12-month P/E multiple of 19.85X, appears somewhat high compared to the industry average of 17.34X. However, this multiple is below the S&P 500's average of 21.91X. Relative to its industry, PG's stock seems pricey.

Due to its premium valuation, Procter & Gamble faces considerable risk should its future financial results disappoint expectations, according to a Yahoo Finance report. 

The intensifying competition within the consumer goods sector, combined with macroeconomic headwinds, could impede the company's ability to maintain its current growth trajectory. 

Furthermore, there is a risk that P&G's current level of innovation and market expansion may prove insufficient to generate substantial future growth, according to the Yahoo Finance report.

Heading into its fiscal third-quarter results, PG presents a balanced near-term risk-reward outlook. The company's defensive business model, strong brand portfolio, and resilient organic growth offer stability amidst a challenging macroeconomic climate. 

Nevertheless, persistent headwinds from commodity inflation, tariff pressures, and fierce competition are likely to continue impacting margins, thereby capping immediate earnings potential, the Yahoo report noted.